Purpose-built for biometrics and regulatory operations, Lodestar™ eliminates submission pipeline fragmentation through AI-assisted, auditable workflow, validated in completed LEARNS clinical study. New York, NY — June 2, 2026 —...
Read More
Completion of data collection enables full analysis, with topline results expected in June 2026 New York, NY — 23 April 2026 — Koneksa, a measurement-science partner for clinical development,...
Read More
Inclusion across leading analyses reflects growing adoption of digital biomarkers and growing need for more rigorous measurement strategies in clinical development New York, NY — March 17, 2026 —...
Read More
We are happy to announce that our clinical study KH007 (NCT06219629) of Disease Progression in Parkinson's Disease (PD) achieved the last patient in (LPI) on January 10, 2025. This is...
Read More
New York, NY – December 10, 2024 – Koneksa, a healthcare technology company pioneering evidence-based digital biomarkers, announced today a publication in Clinical and Translational Science, titled: “Syndication in Science:...
Read More
NEW YORK–(BUSINESS WIRE)– Koneksa, a healthcare technology company pioneering evidence-based digital biomarkers, announced today the appointment of Eric Luthi as Chief Business Officer. In this newly created role, Mr. Luthibrings...
Read More
NEW YORK--(BUSINESS WIRE)--Koneksa, a healthcare technology company pioneering evidence-based digital biomarkers, announced today that Regeneron has become a member of its Data Syndication Program for the LEARNS observational study. This...
Read More
New York, NY – April 25, 2024 – Koneksa, a healthcare technology company pioneering evidence-based digital biomarkers, announced today first patient enrolled in a pilot study collecting patient-generated health data...
Read More
New York, NY – March 20, 2024 – Koneksa, a healthcare technology company pioneering evidence-based digital biomarkers, announced that Merck, known as MSD outside of the United States and Canada,...
Read More
New York, NY – March 4, 2024 – Koneksa, the evidence-based digital biomarkers company, today announced the appointment of Jessie Bakker, M.S., Ph.D., as Vice President (VP) of Clinical Development....
Read More
NEW YORK–(BUSINESS WIRE)–Koneksa, a healthcare technology company pioneering evidence-based digital biomarkers, announced today that the first patient was enrolled in the LEARNS study, an observational study to determine the measurement...
Read More
NEW YORK–(BUSINESS WIRE)–Koneksa, a healthcare technology company pioneering evidence-based digital biomarkers, today announced the publication of a new multi-domain model for capturing functional status in oncology through connected digital tools...
Read More
NEW YORK–(BUSINESS WIRE)–Koneksa, a healthcare technology company pioneering evidence-based digital biomarkers, today announced the first collaboration in the Koneksa Academic Partnership Program for Parkinson’s Disease (KAPP-PD) to incorporate its Neuroscience...
Read More
NEW YORK–(BUSINESS WIRE)–Koneksa, the evidence-based digital biomarkers company, today announced the appointment of Dave Hurry as Chief Data Officer and Larsson Omberg, Ph.D., as Executive Vice President of Data Science....
Read More
NEW YORK– (BUSINESS WIRE) – Koneksa, the evidence-based digital biomarkers company, announced today a partnership with Beacon Biosignals, the leading computational neurodiagnostics company, to launch a clinical trial to investigate...
Read More
